|
Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy Clinical Trials
2 actively recruiting trials
▲ +1 trial since September 2026
Also known as: Dapagliflozin
Pipeline
Phase 4: 2
Top Sponsors
- The University of Hong Kong1
- Tanta University1
Indications
- Sodium-GLucose coTransporter-2 Inhibitors1
- Fontan1
- Dapagliflozin1
- Heart Disease1
- Cardiovascular Diseases1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.